Chronic Stimulant Abuse and Neurobiological Changes

Introduction to Chronic Stimulant Abuse

• Chronic stimulant abuse can cause long-lasting neurobiological changes that significantly impair an individual's ability to experience normal pleasure and happiness when sober, with changes persisting for months to years after cessation of drug use, and in some cases may be permanent, particularly in adolescents with exposure before age 13 1
• The American College of Clinical Psychology and the National Institute of Mental Health support the understanding that addiction is a chronic brain disease requiring continuous care 2, 3

Neurobiological Changes

• Repeated exposure to stimulants leads to neuroadaptations, including upregulation of striatal dopamine transporter density, increases in serotonergic transporter and receptor density, which can persist even after drug cessation, affecting the prefrontal cortex, nucleus accumbens, amygdala, ventral tegmental area, and striatum 1
• The mesolimbic dopamine pathway plays a crucial role in the spiraling process, with initial drug use triggering dopamine release in the nucleus accumbens, creating pleasurable effects, and repeated exposures leading to neuroadaptations that can escalate drug use and impair self-control, as supported by the National Institute of Health and the American Heart Association 4, 5, 6
• The following table summarizes the key points related to the mesolimbic dopamine pathway:

Treatment and Recovery

• Transcranial electrical stimulation (tES) and transcranial magnetic stimulation (TMS) show promise for addiction treatment, with potential to restore normal function in affected brain regions, and may require multiple sessions over several weeks for lasting effects 7
• Combining behavioral interventions with pharmacotherapy may yield better outcomes, as recommended by medical guidelines
• Medication-assisted therapy (such as methadone, buprenorphine, naltrexone) significantly improves outcomes for opioid use disorder, as recommended by the American College of Physicians, the National Institute of Health, and the American Academy of Family Physicians 4, 3, 8
• A combination of counseling, referral to specialty treatment, and pharmacotherapy is recommended for patients with substance dependence, with longer substance abuse treatment programs that include medication-assisted therapy being more effective than short detoxification programs, as recommended by the American Academy of Family Physicians and the Centers for Disease Control and Prevention 8, 9

Prevention and Risk Assessment

• Genetic vulnerability plays a significant role in addiction, with the COMT genotype being a key factor, as stated by the National Institute of Health and the Annual Review of Medicine 4, 2, 6
• The COMT genotype should be considered as part of a comprehensive addiction risk assessment, particularly in patients with a family history of substance use disorders, adolescents, and patients requiring opioid prescriptions or other potentially addictive medications, with consideration of environmental stressors that may amplify genetic vulnerability, as stated by the National Institute of Health and the Annual Review of Medicine 4, 2, 6
• The Centers for Disease Control and Prevention recommends several prevention strategies for persons who use drugs illicitly, including getting tested for HIV, hepatitis B, and hepatitis C, getting vaccinated against hepatitis A and hepatitis B, and stopping injection drug use to eliminate bloodborne infection risk 9
• For individuals with the higher-risk Val/Val genotype, more cautious prescribing of potentially addictive medications, earlier intervention for problematic substance use patterns, and enhanced monitoring during treatment with addictive substances is recommended, according to the National Institute of Health and the American Heart Association 4, 2, 5